Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil;Variação de peso em usuárias de sistema intra-uterino liberador de levonorgestrel, DIU T-cobre e acetato de medroxiprogesterona no Brasil

Revista da Associacao Medica Brasileira

Volumn 52, Issue 1, 2006, Pages 32-36

  Yela, Daniela Angerame ^a,b   Urbano Monteiro, Ilza Maria ^a   Bahamondes, Luis Guillermo ^a   Del Castillo, Soledad ^a   Bahamondes, Maria Valeria ^a   Fernandes, Arlete ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Cidade Universitaria   (Brazil)

Author keywords

Body mass index; Levonorgestrel intrauterine system; Weight

Indexed keywords

EID: 33646809719     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302006000100019     Document Type: Article

References (27)

1. World Health Organization. Nutrition. Controlling the global obesity epidemic. Geneva: World Health Organization; 2003. (Report of a WHO consultation on nutrition).
2. Kelner K, Helmuth L. Obesity-what is to be done? Science 2003;299:845-58.
3. Pi-Sunneyer X. A clinical view of the obesity problem. Science 2003;299:859-60.
4. Hill JO, Wyatt H R, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003;299:853-55.
5. Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J. Obesity prevalence and trends in Latin- American countries. Obes Rev 2001;2:99-106.
6. Gigante DP, Barros FC, Post CLA, Olinto MTA. Prevalência de obesidade em adultos e seus fatores de risco. Rev Saude Publica 1997;31:236-46.
7. Monteiro CA, Benicio DA, Conde WL, Popkin BM. Shifting obesity trends in Brazil. Eur J Clin Nutr 2000; 54:342-6.
8. Campfield LA, Smith FJ. The pathogenesis of obesity. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13:13-30.
9. World Health Organization. Obesity. Obesity epidemic puts millions at risk from related diseases. Geneva: World Health Organization; 1997.
10. Bahamondes L, Del Castillo S, Tabares G, Arce XE, Perrotti M, Petta CA. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to five years. Contraception 2001,64:223-5.
11. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2003;2:CD003987.
12. Bahamondes L, Diaz J, Petta C, Hall P. Weight variation in users of once-a-month injectable contraceptive CyclofemÒ. Adv Contracept 1998;14:185-92.
13. Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system: a follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999;78:716-21.
14. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copperreleasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
15. Sivin I, Mahgoub SE, McCarthy T, Mishell DR Jr, Shoupe D, Alvarez F, et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 1990;42:361-78.
16. Paul C, Skegg DCG, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception 1997;56:209-14.
17. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82.
18. Diaz J, Bahamondes L, Monteiro I, Petta C, Hildalgo M M, Arce XE Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception 2000;62:59-61.
19. Hassan DF, Petta CA, Aldrighi JM, Bahamondes L, Perrotti M. Weight variation in a cohort of women using copper IUD for contraception. Contraception 2003;68:27-30.
20. nd ed. Oxford: Blackwell Scientific Publications; 1985.
21. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001;19:355-63.
22. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002;65:129-32.
23. Baveja R, Bichille LK, Coyaji KJ, Engineer AD, Gogoi MP, Hazra MN, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception 1989;39:37-52.
24. Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptors. Contraception 1998,58:149-51.
25. Istre O, Trolle B. Treatment of menorrhagia with the LNG-IUS versus endometrial resection. Fertil Steril 2001,76:304-9
26. Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception 2002;65:325-8.
27. Raudaskoski TH, Tomas EI, Paakkari IA, Kauppila AJ, Laatikainen TJ. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas 1995;22:47-53.